Home > Maligne hematologie > Lymfoïde ziekten > Plasmaceldyscrasieën > Multipel myeloom > Cartitude 4 / 68284528MMY3002

Cartitude 4 / 68284528MMY3002

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 15-6-2024, 1:02